5-Amino-1mq Clinical Trial Human

Current Human Clinical Trial Status of 5-Amino-1MQ

As of the current scientific literature, no formal Phase I, Phase II, or Phase III human clinical trials evaluating 5-Amino-1MQ have been conducted or published in peer-reviewed medical journals. The molecule has not received regulatory clearance or approval from the U.S. Food and Drug Administration (FDA) or global regulatory bodies for human administration, clinical treatment, or therapeutic intervention.

Search queries regarding a '5-amino-1mq clinical trial human' frequently stem from interest in its novel biochemical target, yet all available empirical data derive strictly from cell culture models and rodent studies. Investigators seeking to explore this compound must source it strictly as a research compound designated for in vitro and laboratory experimental protocols.

Biochemical Mechanism: Nicotinamide N-Methyltransferase (NNMT) Inhibition

To understand why 5-Amino-1MQ is a primary subject of metabolic research, scientists focus on its role as a selective, membrane-permeable inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT is a cytosolic enzyme responsible for methylating nicotinamide (NAM) using S-adenosylmethionine (SAM) as the methyl donor, producing 1-methylnicotinamide (MNA) and S-adenosylhomocysteine (SAH).

Overexpression of NNMT in adipose tissue and liver cells has been linked in rodent models to reduced intracellular concentrations of nicotinamide and SAM. Because nicotinamide is a critical precursor in the NAD+ salvage pathway, high NNMT activity effectively drains the pool of substrates available for NAD+ synthesis. By selectively inhibiting NNMT, 5-Amino-1MQ prevents the irreversible methylation of NAM, maintaining substrate availability for salvage pathway enzymes such as nicotinamide phosphoribosyltransferase (NAMPT). Detailed breakdowns of these pathways are documented throughout our research library hub.

Preclinical Evidence: Regulating Intracellular NAD+ Levels

In vitro data indicate that inhibiting NNMT with 5-Amino-1MQ leads to a direct increase in intracellular nicotinamide adenine dinucleotide (NAD+) concentrations. NAD+ is an essential coenzyme involved in redox reactions, cellular energy transfer, and sirtuin (SIRT1–SIRT7) activation, which regulate cellular stress responses and mitochondrial biogenesis.

Preclinical studies suggest that when 3T3-L1 adipocyte cell lines are treated with 5-Amino-1MQ, the reduction in NNMT activity prevents metabolic flux toward MNA, subsequently increasing NAD+ synthesis. This elevation in intracellular NAD+ enhances SIRT1 signaling, providing researchers with a valuable model to examine sirtuin-dependent pathways without relying on direct NAD+ precursors.

Mitochondrial Output and Adipocyte Energy Expenditure

Mitochondrial dysfunction and reduced bioenergetic output are central themes in metabolic disease models. Preclinical studies evaluating diet-induced obese (DIO) rodent models demonstrate that 5-Amino-1MQ administration alters cellular oxygen consumption rates (OCR) and basal metabolic rate without reducing total caloric intake.

Investigators measuring mitochondrial respiration in cultured adipocytes have observed increased basal and maximal oxygen consumption following NNMT inhibition. This suggests that 5-Amino-1MQ promotes mitochondrial biogenesis and uncoupled respiration in fat-metabolism research, causing adipocytes to dissipate energy as heat rather than storing it as lipid droplets. Researchers can explore additional bioenergetic mechanisms via our catalog of all peptides and small molecules.

Comparative Preclinical Research: 5-Amino-1MQ vs. Metabolic Peptides

In cellular and animal models of energy expenditure, researchers frequently compare small-molecule NNMT inhibitors like 5-Amino-1MQ to peptidergic regulators of metabolism. While 5-Amino-1MQ targets cytosolic methyltransferase activity to preserve NAD+, peptide compounds operate through distinct cell-surface or organelle-specific pathways.

For instance, mitochondrial-derived peptides like MOTS-c target nuclear transcription factors to regulate folate cycle and glucose metabolism, whereas lipolytic fragments such as AOD-9604 act via beta-3 adrenergic pathways to stimulate lipid hydrolysis. Similarly, growth hormone secretagogue analogs like Tesamorelin promote endogenous GH release to influence visceral adiposity. Comparative studies evaluating these distinct mechanisms allow laboratories to map non-overlapping pathways in cellular metabolic regulation.

In Vitro Specificity and Enzyme Kinetics

A critical factor in evaluating 5-Amino-1MQ for laboratory research is its enzymatic selectivity. In cell-free biochemical assays, 5-Amino-1MQ demonstrates low micromolar IC50 values against human NNMT while showing minimal cross-reactivity with related methyltransferases such as histamine N-methyltransferase (HNMT) or indolethylamine N-methyltransferase (INMT).

This structural selectivity ensures that observed experimental outcomes—such as altered SAM/SAH ratios or elevated intracellular NAD+—can be confidently attributed to NNMT inhibition rather than off-target epigenetic or neurotransmitter methylation alterations. Researchers interested in enzyme kinetics and substrate dynamics can consult specialized studies on NNMT inhibitors and NAD pathways.

Laboratory Handling, Reconstitution, and Solubilization Parameters

5-Amino-1MQ is a synthetic small-molecule quinolinium derivative supplied typically as a crystalline solid or lyophilized powder. For optimal stability in laboratory assays, precise handling and reconstitution protocols must be maintained:

1. **Solubility**: 5-Amino-1MQ exhibits high solubility in dimethyl sulfoxide (DMSO) and organic solvents, with limited solubility in purely aqueous buffers at neutral pH. Stock solutions should be prepared in sterile DMSO and diluted into culture media immediately prior to cell treatment.

2. **Storage**: Lyophilized powder should be stored sealed at -20°C in a desiccated environment. Reconstituted stock solutions in DMSO should be aliquoted and maintained at -80°C to prevent degradation from repeated freeze-thaw cycles.

3. **In Vitro Working Concentrations**: In cell culture protocols, working concentrations typically range between 1 µM and 50 µM, depending on the specific cell line and incubation duration.

Analytical Verification: Quality Standards for Research Compounds

Because non-clinical research requires highly reproducible data, researchers must verify the structural identity and purity of 5-Amino-1MQ prior to assay integration. Impurities in small-molecule inhibitors can induce cytotoxic effects or non-specific enzymatic inhibition, invalidating experimental outcomes.

PX1 Research enforces stringent analytical testing protocols for every lot of 5-Amino-1MQ. Compounds undergo high-performance liquid chromatography (HPLC) to confirm mass purity (>98%) and liquid chromatography-mass spectrometry (LC-MS) to verify molecular weight and structure. Furthermore, every batch is screened for bacterial endotoxins using chromogenic Limulus Amebocyte Lysate (LAL) assays, ensuring suitability for delicate cell culture systems.

Sourcing High-Purity 5-Amino-1MQ for Institutional Research

Acquiring reliable research compounds requires a supplier committed to quality control and transparency. PX1 Research manufactures and tests products within USA-based, ISO 17025-accredited laboratory environments operating under GMP-compliant facility standards.

Every shipment includes a lot-specific Certificate of Analysis (COA) detailing raw HPLC chromatograms and mass spectra. Orders ship same-day (Monday through Friday) from centralized fulfillment centers in California and Arizona. Principal investigators and institution managers seeking high-volume orders for ongoing studies can set up dedicated accounts through our wholesale lab portal.